azomycin has been researched along with rb 6145 in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 24 (75.00) | 18.2507 |
| 2000's | 6 (18.75) | 29.6817 |
| 2010's | 2 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stratford, IJ | 1 |
| Adams, GE; Bedwell, J; Bown, SG; Bremner, JC; MacRobert, AJ; Pearson, JK; Phillips, D; Sansom, JM; Stratford, IJ | 1 |
| Beningo, KA; Elliott, WL; Heffner, TG; Leopold, WR; Sebolt-Leopold, JS; Stier, MA; Suto, MJ; Vincent, PW; Wiley, JN | 1 |
| Chaplin, DJ | 1 |
| Adams, GE; Bremner, JC; Cole, S; Edwards, HS; Stratford, IJ | 1 |
| Adams, GE; Cole, S; Elliott, W; Fielden, EM; Leopold, W; Sebolt-Leopold, J; Stratford, IJ; Suto, M | 1 |
| Binger, M; Workman, P | 1 |
| Stier, MA; Suto, MJ; Werbel, LM | 1 |
| Adams, GE; Bremner, JC; Edwards, HS; Fielden, EM; Stratford, IJ | 1 |
| Adams, GE; Bowler, J; Cole, S; Lorimore, SA; Nolan, J; Stratford, IJ; Wright, EG | 1 |
| Siemann, DW | 2 |
| Adams, GE; Butler, SA; Cole, SM; Sansom, JM; Stratford, IJ; Szabo, C; Thiemermann, C; Wood, PJ | 1 |
| Adams, GE; Stratford, IJ | 1 |
| Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ | 1 |
| Adams, GE; Fielden, EM; Naylor, MA; Showalter, HD; Stephens, MA; Stratford, IJ; Threadgill, MD | 1 |
| Bremner, JC | 1 |
| Acheson, DK; Chaplin, DJ; Heinrichs, BE; Loblaw, DA; Minchinton, AI; Skarsgard, LD; Vinczan, A; Wouters, BG | 1 |
| Arnold, S; Chaplin, DJ; Collingridge, D; Hill, SA; Horsman, MR; Overgaard, J; Radacic, M; Wood, PJ | 1 |
| Adams, GE; Horsman, MR; Khalil, AA; Overgaard, J; Steinberg, F; Stratford, IJ; Streffer, C; Wood, PJ | 1 |
| Skarsgard, LD; Wouters, BG | 1 |
| Adams, GE; Butler, SA; Cole, S; Stratford, IJ; Williams, C; Wood, PJ | 1 |
| Bullen, WW; Hoffman, KL; Lathia, CD; Rossi, DT; Suri, A | 1 |
| Baguley, BC; Lash, CJ; Li, AE; Rutland, M; Wilson, WR; Zwi, LJ | 1 |
| Lee, AE; Wilson, WR | 1 |
| Airley, R; Cowen, RL; Honess, D; Jaffar, M; Patterson, AV; Saunders, M; Stratford, IJ; Telfer, BA; van der Kogel, AJ; Williams, KJ; Wolf, CR | 1 |
| Banáth, JP; Durand, RE; Olive, PL | 1 |
| Dethloff, LA; Miller, TJ; Phelka, AD; Philbert, MA; Tjalkens, RB | 1 |
| Fitzmaurice, RJ; Lunt, SJ; Stratford, IJ; Telfer, BA; Williams, KJ | 1 |
| Agarwal, N; Al-Ubaidi, MR; Dethloff, LA; Martin, BP; Miller, JA; Miller, TJ; Philbert, MA; Schneider, RJ | 1 |
| Ali, M; Babur, M; Bloomer, WD; Cawthorne, C; Julyan, PJ; Lunt, SJ; Papadopoulou, MV; Price, PM; Smigova, A; Stratford, IJ; Telfer, BA; Williams, KJ | 1 |
| Elliott, W; Leopold, J; Leopold, W; Sercel, A; Showalter, H; Suto, C; Winters, T | 1 |
2 review(s) available for azomycin and rb 6145
| Article | Year |
|---|---|
Bioreductive drugs in cancer therapy.
Topics: Animals; Antineoplastic Agents; Antioxidants; Cell Hypoxia; Humans; Misonidazole; Neoplasms; Nitroimidazoles; Prodrugs; Radiation-Sensitizing Agents; Tirapazamine; Triazines | 1992 |
Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line; Cell Survival; Humans; Misonidazole; Neoplasms, Experimental; Nitroimidazoles; Oxidation-Reduction; Prodrugs; Radiation-Sensitizing Agents | 1993 |
30 other study(ies) available for azomycin and rb 6145
| Article | Year |
|---|---|
Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.
Topics: Animals; Indoles; Mice; Misonidazole; Nitroimidazoles; Organometallic Compounds; Photochemotherapy; Sarcoma; Tumor Cells, Cultured | 1992 |
Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.
Topics: Animals; Antiemetics; Dogs; Drug Evaluation; Imidazoles; Mice; Misonidazole; Nitroimidazoles; Ondansetron; Radiation-Sensitizing Agents; Vomiting | 1992 |
Bioreductive therapy.
Topics: Antineoplastic Agents; Cell Hypoxia; Humans; Misonidazole; Nitroimidazoles; Oxidation-Reduction; Prodrugs; Radiation-Sensitizing Agents; Tirapazamine; Triazines | 1992 |
Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
Topics: Animals; Antineoplastic Agents; Aziridines; Cell Hypoxia; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Indolequinones; Indoles; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Prodrugs; Tirapazamine; Triazines | 1992 |
Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
Topics: Animals; Cell Hypoxia; Combined Modality Therapy; Drug Evaluation; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental | 1992 |
Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Female; Half-Life; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Prodrugs; Sarcoma, Experimental | 1991 |
Dual-function radiosensitizers. Alpha-[[(2-bromoethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanol and related compounds: preparation via an aziridine equivalent.
Topics: Acetates; Acetic Acid; Aziridines; Chemical Phenomena; Chemistry; Esterification; Molecular Structure; Nitroimidazoles; Oxazoles; Oxazolidinones; Prodrugs; Radiation-Sensitizing Agents | 1991 |
Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs.
Topics: Antineoplastic Agents; Combined Modality Therapy; Humans; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1991 |
Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
Topics: Administration, Oral; Animals; Combined Modality Therapy; Injections, Intraperitoneal; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental | 1991 |
Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872.
Topics: Animals; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Lomustine; Mice; Nitroimidazoles; Prodrugs; Sarcoma, Experimental; Stereoisomerism; Tumor Cells, Cultured | 1995 |
Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine.
Topics: Animals; Arginine; Carcinoma; Cell Hypoxia; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Energy Metabolism; Female; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred C3H; Nitroarginine; Nitroimidazoles; Phosphates; Prodrugs; Sarcoma, Experimental | 1994 |
Bioreductive drugs for cancer therapy: the search for tumor specificity.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Nitric Oxide; Nitroimidazoles; Oxidation-Reduction; Photochemotherapy; Porfiromycin; Prodrugs; Tirapazamine; Triazines | 1994 |
In vitro cytotoxicity and chemosensitizing activity of the dual function nitroimidazole RB 6145.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Humans; Lomustine; Mice; Nitroimidazoles; Prodrugs; Stereoisomerism; Tumor Cells, Cultured | 1994 |
Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Topics: Animals; Antineoplastic Agents; Mice; Mice, Inbred C3H; Misonidazole; Mitomycin; Nitroimidazoles; Photochemotherapy; Sarcoma, Experimental | 1994 |
Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro.
Topics: Antineoplastic Agents; Misonidazole; Nitroimidazoles; Prodrugs; Radiation-Sensitizing Agents; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
Cytotoxic effect of RB 6145 in human tumour cell lines: dependence on hypoxia, extra- and intracellular pH and drug uptake.
Topics: Cell Hypoxia; Chromatography, High Pressure Liquid; Extracellular Space; HT29 Cells; Humans; Hydrogen-Ion Concentration; Intracellular Fluid; Nitroimidazoles; Prodrugs; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1995 |
Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Female; Hyperthermia, Induced; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred CBA; Nitroarginine; Nitroimidazoles; Regional Blood Flow; Sarcoma, Experimental | 1996 |
A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease Models, Animal; Female; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred C3H; Misonidazole; Neovascularization, Pathologic; Nitroimidazoles; Oxygen; Phosphorus Radioisotopes | 1996 |
Substructure in the cell survival response at low radiation dose: effect of different subpopulations.
Topics: Animals; Cell Separation; Cell Survival; Cricetinae; Dose-Response Relationship, Radiation; Etanidazole; Humans; Nitroimidazoles; Oxygen; Relative Biological Effectiveness; Tumor Cells, Cultured; X-Rays | 1997 |
Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Survival; Drug Synergism; Enzyme Inhibitors; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Nitric Oxide Synthase; Nitroarginine; Nitroimidazoles | 1997 |
An HPLC assay utilizing solid-phase extraction for CI-1010, an alkylating radiosensitizer, in rat plasma.
Topics: Alkylating Agents; Animals; Chromatography, Liquid; Drug Stability; Injections, Intravenous; Nitroimidazoles; Prodrugs; Radiation-Sensitizing Agents; Rats; Reproducibility of Results; Spectrophotometry, Ultraviolet | 1997 |
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Mice; Mice, Inbred C3H; Nitrogen Mustard Compounds; Nitroimidazoles; Prodrugs; Regional Blood Flow; Serotonin; Tirapazamine; Triazines; Xanthenes; Xanthones | 1998 |
Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hypoxia; Light; Mice; Mice, Inbred C57BL; Nitroimidazoles; Oxidation-Reduction; Prodrugs; Radiation-Sensitizing Agents; Retina; Tirapazamine; Triazines | 2000 |
Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours.
Topics: Animals; Combined Modality Therapy; Female; Fibrosarcoma; Genetic Therapy; Genetic Vectors; Humans; Hypoxia; Mice; Mice, Nude; Misonidazole; NADPH-Ferrihemoprotein Reductase; Neoplasm Transplantation; Nitroimidazoles; Prodrugs; Radiation Tolerance; Radiation-Sensitizing Agents; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
The range of oxygenation in SiHa tumor xenografts.
Topics: Animals; Carcinoma; Cell Survival; Comet Assay; DNA Damage; Female; Humans; In Vitro Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Misonidazole; Nitroimidazoles; Oxygen Consumption; Radiation-Sensitizing Agents; Transplantation, Heterologous; Uterine Cervical Neoplasms | 2002 |
CI-1010 induced opening of the mitochondrial permeability transition pore precedes oxidative stress and apoptosis in SY5Y neuroblastoma cells.
Topics: Antioxidants; Apoptosis; Brain Neoplasms; Cell Death; Cell Survival; DNA Fragmentation; Flow Cytometry; Humans; In Situ Nick-End Labeling; Membrane Potentials; Microscopy, Electron; Mitochondria; Neuroblastoma; Nitroimidazoles; Oxidative Stress; Permeability; Photoreceptor Cells; Radiation-Sensitizing Agents; Reactive Oxygen Species; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured; Vitamin E | 2003 |
Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Female; Hypoxia; Mice; Mice, Inbred C3H; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental; Tirapazamine; Treatment Outcome; Triazines | 2005 |
Photoreceptor cell apoptosis induced by the 2-nitroimidazole radiosensitizer, CI-1010, is mediated by p53-linked activation of caspase-3.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspase 3; Cell Cycle; Cell Line, Transformed; DNA Damage; Dose-Response Relationship, Drug; Fas Ligand Protein; Flow Cytometry; Mice; Nitroimidazoles; Photoreceptor Cells; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Radiation-Sensitizing Agents; Time Factors; Tumor Suppressor Protein p53 | 2006 |
The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation, Preclinical; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred C3H; Neoplasm Metastasis; Nitroimidazoles; Quinolines; Sarcoma; Tirapazamine; Triazines | 2010 |
Design and synthesis of 2-nitroimidazoles with variable alkylating and acylating functionality.
Topics: Acylation; Alkylating Agents; Animals; Drug Design; Drug Screening Assays, Antitumor; Mice; Misonidazole; Nitroimidazoles; Radiation-Sensitizing Agents; Structure-Activity Relationship | 2014 |